Gossamer Bio targets September seralutinib NDA; HC Wainwright raises PT

Gossamer Bio said it remains on track to file an NDA for seralutinib for pulmonary arterial hypertension in September. HC Wainwright kept a Buy and raised its price target to $90 from $2.